Literature DB >> 20398070

Thrombin generation in patients with factor XI deficiency and clinical bleeding risk.

L Rugeri1, F Quélin, B Chatard, P De Mazancourt, C Negrier, Y Dargaud.   

Abstract

SUMMARY: Factor XI (FXI) deficiency is a rare bleeding disorder. Most patients with FXI deficiency are mild bleeders but certain patients with similar FXI activity exhibit different bleeding phenotype. Routine laboratory assays do not help physicians to estimate the individual bleeding risk in these patients. Thrombin generation test (TGT) is a more comprehensive, global function test of the clotting system. We investigated whether or not the bleeding tendency of patients with FXI deficiency is correlated with features of the TGT. Twenty-four patients with FXI deficiency were divided in two groups: (i) severe bleeders (n = 9) and (ii) mild or non-bleeders (n = 15). All severe bleeders had a personal history of surgery-related severe bleeding. Thrombin generation (TG) was measured in platelet-rich plasma (PRP) using a low concentration of tissue factor 0.5 pm. In patients exhibiting severe bleeding tendency, independently of their FXI level, a dramatically impaired TG was observed. For example, despite a low plasma FXI = 1 IU dl(-1), a clinically non-bleeding individual exhibited normal TG results whereas another patient with severe bleeding history and FXI = 40 IU dl(-1) had a very low TG capacity. Low velocity and delayed TG were the main parameters suggesting a higher bleeding risk. DNA analysis of patients reported eight novel mutations of the FXI gene but neither mutation location nor secretion or not of the variant correlated with the bleeding tendency. The results of this study suggest that TG measurement in PRP may be a useful tool to predict bleeding risk in FXI deficiency and should be studied further in larger prospective clinical studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20398070     DOI: 10.1111/j.1365-2516.2010.02246.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

Review 1.  Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.

Authors:  P James; O Salomon; D Mikovic; F Peyvandi
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

2.  Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.

Authors:  Y Dargaud; A S Wolberg; E Gray; C Negrier; H C Hemker
Journal:  J Thromb Haemost       Date:  2017-06-28       Impact factor: 5.824

3.  The clinical management of factor XI deficiency in pregnant women.

Authors:  Allison P Wheeler; Celeste Hemingway; David Gailani
Journal:  Expert Rev Hematol       Date:  2020-06-12       Impact factor: 2.929

4.  Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.

Authors:  M Zucker; U Seligsohn; O Salomon; A S Wolberg
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

5.  Functional investigation of a venous thromboembolism GWAS signal in a promoter region of coagulation factor XI gene.

Authors:  Minyoung Kong; Younyoung Kim; Chaeyoung Lee
Journal:  Mol Biol Rep       Date:  2014-01-14       Impact factor: 2.316

6.  Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

Authors:  Gillian N Gidley; Lori A Holle; John Burthem; Paula H B Bolton-Maggs; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-05-22

Review 7.  Global assays of hemostasis.

Authors:  Kathleen E Brummel-Ziedins; Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

8.  Assessing the individual roles of FII, FV, and FX activity in the thrombin generation process.

Authors:  Cuicui Bai; Joke Konings; Marisa Ninivaggi; Marcus Lancé; Bas de Laat; Romy de Laat-Kremers
Journal:  Front Cardiovasc Med       Date:  2022-09-20

9.  Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy.

Authors:  C P D M de Breet; S Zwaveling; M J A Vries; R G van Oerle; Y M C Henskens; A W J Van't Hof; P E J van der Meijden; L Veenstra; H Ten Cate; R H Olie
Journal:  Front Cardiovasc Med       Date:  2021-06-10

Review 10.  Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets.

Authors:  Marina Panova-Noeva; Paola E J van der Meijden; Hugo Ten Cate
Journal:  J Clin Med       Date:  2019-12-30       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.